Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
341-360 of 1,782 trials

Colorectal Cancer: Post-Surgery Chemotherapy Study

We are investigating whether restarting chemotherapy after surgery helps patients with colorectal cancer that has spread to the liver live longer and stay cancer-free. This study compares different treatment approaches to find the best option.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Sotatercept for Children with Pulmonary Artery Hypertension

We are studying the safety and effects of sotatercept in children aged 1 to under 18 with pulmonary artery hypertension. This research aims to improve treatment options for young patients already receiving standard care.

Pulmonary Arterial Hypertension3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyPulmonology

Pediatric Cancer: Crizotinib Treatment Study

We are testing the safety and effectiveness of crizotinib, alone and with temsirolimus, for children with ALK, ROS1, or MET positive cancers. This study aims to find the best dose and understand how well these treatments work.

NeuroblastomaAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Chronic Kidney Disease: Finerenone Safety Study

We are studying the long-term safety of finerenone for children and young adults with chronic kidney disease. This trial looks at its effects when used alongside standard treatments like ACE inhibitors or ARBs.

Chronic Kidney DiseaseProteinuria1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Advanced Thyroid Cancer: Sacituzumab Govitecan Study

We are testing a new drug for patients with advanced differentiated and anaplastic thyroid neoplasms. The goal is to see if it can effectively control the disease and improve patient outcomes.

Thyroid Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Progressive Pulmonary Fibrosis: Inhaled Treprostinil Study

We are investigating whether inhaled treprostinil can improve lung function in people with progressive pulmonary fibrosis. The study will also assess its safety and impact on overall health.

Progressive Pulmonary Fibrosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPulmonology

Non-Transfusion-Dependent Thalassemia: Luspatercept Treatment

We are studying whether luspatercept can improve brain oxygen levels and blood flow in patients with non-transfusion-dependent thalassemia. The trial also looks at its effects on cognitive function and heart health.

Non-transfusion Dependent Beta-Thalassemia6-12 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHematologyNeurology

Prostate Cancer: 177Lu-PSMA Treatment Study

We are studying a new treatment for men with high-risk prostate cancer after initial therapies. The trial aims to see if this treatment helps prevent cancer from coming back and improves quality of life.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Dobutamine for Very Preterm Infants with Low Blood Flow

We are studying the lowest effective dose of dobutamine to help improve blood flow in very preterm infants. The trial also looks at how well the treatment works and its safety during the first few days after birth.

Neonates with Haemodynamic Insufficiency>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCardiologyPediatrics

Prostate Cancer Recurrence: PSMA PET/CT vs. Salvage Radiotherapy

We are comparing a personalized treatment approach using PSMA PET/CT imaging with standard salvage radiotherapy for patients whose prostate cancer has returned after surgery. The goal is to see which method better helps manage their condition and improves quality of life.

Recurrent Prostate Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Breast Cancer Treatment: Elacestrant with Olaparib

We are studying whether adding elacestrant to the standard treatment olaparib helps women with hormone receptor-positive, HER2-negative breast cancer and gBRCA1/2 mutations. This trial aims to improve progression-free survival and overall treatment outcomes.

Metastatic Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Cancer Treatment: Imipramine for Fascin1 Overexpression

We are studying whether Imipramine can change tumor characteristics in patients with cancer that over-express a protein called Fascin1. This research may help us understand its effects on tumor behavior and markers.

Colon and Rectal Cancer3-6 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyOncology

HIV and Liver Health: Doravirine Study

We are exploring how the medication Doravirine affects liver fat and fibrosis in people living with HIV who have liver issues. This study aims to see if switching to Doravirine improves liver health over time.

Human Immunodeficiency Virus (HIV)1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesHepatologyInfectious DiseasesInternal Medicine

Cervical Cancer: Surgery Plus Therapy Study

We are investigating whether additional therapy after surgery helps patients with early-stage, intermediate-risk cervical cancer stay cancer-free. This study compares outcomes with and without further treatment.

Early-Stage Cervical Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Surgical Site Infection Prevention: Linezolid vs. Vancomycin

We are studying whether linezolid is as effective as vancomycin in preventing infections after surgery. This trial includes various surgeries and looks at infection rates and patient experiences.

Surgical Antibiotic Prophylaxis>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Advanced Breast Cancer: Capivasertib with CDK4/6 Inhibitors

We are studying a new treatment combining capivasertib with CDK4/6 inhibitors and fulvestrant for patients with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this combination improves treatment outcomes compared to standard therapies.

Hormone Receptor-Positive and HER2-Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Quizartinib for Pediatric FLT3-ITD Positive AML

We are studying the safety and effectiveness of quizartinib combined with chemotherapy in children and adolescents newly diagnosed with FLT3-ITD positive acute myeloid leukemia. This trial aims to see if it helps improve treatment outcomes compared to standard therapies.

Pediatric Acute Myeloid Leukemia (AML)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Prostate Cancer: New Treatment Combining Radiation and Antiandrogen

We are studying a new treatment approach for men with advanced prostate cancer to see if combining radiation therapy with a second-generation antiandrogen improves outcomes. The trial will also look at quality of life and any side effects from the treatment.

Oligometastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Colchicine for Heart Health After PCI

We are studying whether colchicine can help reduce serious heart events in patients with coronary artery disease after a heart procedure. This trial compares colchicine to a placebo to see its effects on heart health.

Coronary Artery DiseaseConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyInternal Medicine

Non-Seminomatous Germ-Cell Tumors: Personalized Treatment Study

We are exploring new treatment strategies for young adults with poor-prognosis non-seminomatous germ-cell tumors. This study aims to improve outcomes through personalized care and early assessments.

Germ Cell Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology